Larvin

Clopidogrel, the active ingredient in Larvin, is an antiplatelet agent presented as an oral tablet for systemic use. It inhibits platelet aggregation and is used to reduce the risk of atherothrombotic events in patients with cardiovascular disease. GNH USA supplies Larvin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Clopidogrel is indicated for conditions involving platelet‑mediated arterial thrombosis. - Acute coronary syndrome: lowers the risk of recurrent myocardial infarction and cardiovascular death. - Stroke prevention: reduces the incidence of ischemic stroke in patients with prior cerebrovascular events. - Peripheral arterial disease: improves walking distance and decreases limb‑related events. - Atherothrombotic event prevention: diminishes the likelihood of heart attack, stroke, or vascular death in high‑risk patients.

Clopidogrel may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Bleeding gums or easy bruising - Diarrhea or abdominal discomfort - Nausea or vomiting - Headache - Rash or pruritus

Serious or Rare Side Effects: - Severe or uncontrolled bleeding - Thrombotic thrombocytopenic purpura - Neutropenia or agranulocytosis - Hepatic failure or transaminase elevation - Severe allergic reactions including anaphylaxis - Stevens‑Johnson syndrome or toxic epidermal necrolysis

Before initiating therapy, clinicians should evaluate bleeding risk and monitor patients regularly. - Assess bleeding risk: review history of gastrointestinal ulcers or hemorrhage. - Monitor platelet function: periodic laboratory checks may be warranted. - Review concomitant anticoagulants: adjust therapy to avoid excessive bleeding. - Adjust in hepatic impairment: use with caution in patients with liver disease. - Avoid in active pathological bleeding: discontinue if severe bleeding occurs. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Clopidogrel interacts with several drug classes that can alter its efficacy or safety.

Major Interactions (Avoid): - Proton pump inhibitors (e.g., omeprazole): may reduce clopidogrel activation. - Strong CYP2C19 inhibitors (e.g., fluoxetine, ticagrelor): decrease conversion to active metabolite. - Anticoagulants (e.g., warfarin, heparin): increase risk of major bleeding.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower plasma levels. - Non‑steroidal anti‑inflammatory drugs (e.g., ibuprofen): add to bleeding risk.